ASCO: Results of ENCORE 602

Abstract No : 1014

Abstract Type : Poster Discussion Session

Indication : Triple Negative Breast Cancer

Intervention : entinostat + atezolizumab

Company : Syndax Pharmaceutical Inc.

Technology : Monoclonal antibody


81 pts. were enrolled, median age 56 years (range 29-87), 69% received 1 prior line of therapy and 31% . 1 line. No significant difference in PFS per RECIST 1.1 was observed between ATEZO+ENT and ATEZO+P (median PFS 1.68 and 1.51 months, respectively [p = 0.64; HR 0.89, 95% CI: 0.53-1.48]), nor in any of the secondary efficacy endpoints (median PFS per irRECIST 1.68 vs 1.54 months; ORR 10.0% vs 2.4%; CBR 37.5% vs 31.7%; median OS 9.8 vs 12.4 months, respectively). Frequency of treatment-emergent adverse events (TEAEs), SAEs, discontinuations due to TEAE and TEAE with outcome death were higher in the ENT+ATEZO arm


In pts. with previously treated aTNBC, median PFS was not prolonged when ENT was added to ATEZO compared to ATEZO and placebo, and the combination resulted in greater toxicity.


Entinostat + Atezolizumab did not improve progression free survival, resulted in greater toxicity than placebo and atezolizumab hence, as per Delveinsight's analysis this is not a safe and effective treatment option for relapse/refractory Triple Negative Breast Cancer patients.

Refer to Triple Negative Breast Cancer Market report for detailed Insights.